Literature DB >> 10462552

The N terminus domain of type VI adenylyl cyclase mediates its inhibition by protein kinase C.

H L Lai1, T H Lin, Y Y Kao, W J Lin, M J Hwang, Y Chern.   

Abstract

Previous results from our laboratory have shown that phosphorylation of type VI adenylyl cyclase (ACVI) by protein kinase C (PKC) caused suppression of adenylyl cyclase activity. In the present study, we investigated the role of the N terminus cytosolic domain of ACVI in this PKC-mediated inhibition of ACVI. Removal of amino acids 1 to 86 of ACVI or mutation of Ser(10) (a potential PKC phosphorylation site) into alanine significantly relieved the PKC-mediated inhibition and markedly reduced the PKC-evoked protein phosphorylation. PKC also effectively phosphorylated a recombinant N terminus cytosolic domain (amino acids 1-160) protein of ACVI and a synthetic peptide representing Ser(10). In addition, the amino acids 1 to 86 truncated mutant exhibited kinetic properties similar to those of the wild type. Taken together, these data demonstrate that the highly variable N terminus cytoplasmic domain of ACVI is a regulatory domain with a critical role in PKC-mediated suppression, which is a hallmark of this adenylyl cyclase isozyme. In addition, Ser(10) was found to serve as an acceptor for the PKC-mediated phosphorylating transfer of ACVI.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462552     DOI: 10.1124/mol.56.3.644

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Regulation of type V adenylate cyclase by Ric8a, a guanine nucleotide exchange factor.

Authors:  Shyi-Chyi Wang; Hsing-Lin Lai; Yi-Ting Chiu; Ren Ou; Chuen-Lin Huang; Yijuang Chern
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

Review 2.  Regulation and organization of adenylyl cyclases and cAMP.

Authors:  Dermot M F Cooper
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

3.  N terminus of type 5 adenylyl cyclase scaffolds Gs heterotrimer.

Authors:  Rachna Sadana; Nathan Dascal; Carmen W Dessauer
Journal:  Mol Pharmacol       Date:  2009-09-25       Impact factor: 4.436

4.  Type VI adenylyl cyclase regulates neurite extension by binding to Snapin and Snap25.

Authors:  Chia-Shan Wu; Jiun-Tsai Lin; Chen-Li Chien; Wei-Cheng Chang; Hsing-Lin Lai; Ching-Pang Chang; Yijuang Chern
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

5.  Second messenger-dependent protein kinases and protein synthesis regulate endogenous secretin receptor responsiveness.

Authors:  Roxana S Ghadessy; Eamonn Kelly
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

6.  Adenylyl Cyclase 5 Regulation by Gβγ Involves Isoform-Specific Use of Multiple Interaction Sites.

Authors:  Cameron S Brand; Rachna Sadana; Sundeep Malik; Alan V Smrcka; Carmen W Dessauer
Journal:  Mol Pharmacol       Date:  2015-07-23       Impact factor: 4.436

Review 7.  Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies.

Authors:  Rachna Sadana; Carmen W Dessauer
Journal:  Neurosignals       Date:  2008-10-24

8.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  The type VI adenylyl cyclase protects cardiomyocytes from β-adrenergic stress by a PKA/STAT3-dependent pathway.

Authors:  Yu-Shuo Wu; Chien-Chang Chen; Chen-Li Chien; Hsing-Lin Lai; Si-Tse Jiang; Yong-Cyuan Chen; Lin-Ping Lai; Wei-Fan Hsiao; Wen-Pin Chen; Yijuang Chern
Journal:  J Biomed Sci       Date:  2017-09-04       Impact factor: 8.410

Review 10.  Current Landscape of Heart Failure Gene Therapy.

Authors:  Jake M Kieserman; Valerie D Myers; Praveen Dubey; Joseph Y Cheung; Arthur M Feldman
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.